.png)
Antibody Drug Conjugates Market By Drugs, Mechanism Of Action and Application - Global Industry Analysis & Forecast to 2027
Published On : March 2019 Pages : 165 Category: Pharma & Healthcare Report Code : HC032982
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Antibody Drug Conjugates Market By Drugs (Kadcyla, Adcetris) Mechanism Of Action (HER2 Antibodies, CD30 Antibodies) Application (Lymphoma, Breast Cancer) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Antibody Drug Conjugates Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Antibody drug conjugates are very powerful biopharmaceutical drugs produced by incorporating two standards for example a cell killing highly powerful active pharmaceutical ingredient (HPAPI) and unequivocal nature of monoclonal antibodies. They are exceptionally powerful anticancer medications focusing on just disease tainted cells accordingly, leaving solid uninfected cell unblemished encouraging snappy recuperation of cancer patients.
Drivers and Restraints
Increment in pervasiveness of cancer and increasing demand for productive and cost-effective disease medications drive the market. In addition, broad research on medication improvement and extensive number of pipeline drugs for ADCs present in various phases of endorsements are anticipated to help the market development. Approvals of pipelined drugs increment the quantity of accessible ADC products, in total impelling business sector turnover of ADCs.
Regional Insights
North America holds the most noteworthy piece of the overall industry in 2017 inferable from high pervasiveness of disease in the district and present day medicinal services offices for work of novel therapeutic strategies.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Novartis AG
- Pfizer, Inc
- Genentech Inc
- Immunomedics, Inc
- Bayer Healthcare Pharmaceuticals
- F. Hoffman-La Roche Ltd
- Takeda Pharmaceutical Company Limited
- Seattle Genetics Inc
- Immunogen Inc
- Progenics Pharmaceuticals Inc
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Antibody Drug Conjugates Market, By Drugs, Estimates and Forecast, 2017-2027($Billion)
o Kadcyla
o Adcetris
· Antibody Drug Conjugates Market, By Mechanism Of Action, Estimates and Forecast, 2017-2027($Billion)
o HER2 Antibodies
o CD30 Antibodies
· Antibody Drug Conjugates Market, By Application, Estimates and Forecast, 2017-2027($Billion)
o Lymphoma
o Breast Cancer
· Antibody Drug Conjugates Market, By Region, Estimates and Forecast, 2017-2027($Billion)
o North America
§ North America Antibody Drug Conjugates Market, By Country
o U.S. Antibody Drug Conjugates Market
o Canada Antibody Drug Conjugates Market
o Mexico Antibody Drug Conjugates Market
o Europe
§ Europe Antibody Drug Conjugates Market, By Country
o Germany Antibody Drug Conjugates Market
o UK Antibody Drug Conjugates Market
o France Antibody Drug Conjugates Market
o Russia Antibody Drug Conjugates Market
o Italy Antibody Drug Conjugates Market
o Rest of Europe Antibody Drug Conjugates Market
o Asia-Pacific
§ Asia-Pacific Antibody Drug Conjugates Market, By Country
o China Antibody Drug Conjugates Market
o Japan Antibody Drug Conjugates Market
o South Korea Antibody Drug Conjugates Market
o India Antibody Drug Conjugates Market
o Southeast Asia Antibody Drug Conjugates Market
o Rest of Asia-Pacific Antibody Drug Conjugates Market
o South America
§ South America Antibody Drug Conjugates Market
o Brazil Antibody Drug Conjugates Market
o Argentina Antibody Drug Conjugates Market
o Columbia Antibody Drug Conjugates Market
o Rest of South America Antibody Drug Conjugates Market
o Middle East and Africa
§ Middle East and Africa Antibody Drug Conjugates Market
o Saudi Arabia Antibody Drug Conjugates Market
o UAE Antibody Drug Conjugates Market
o Egypt Antibody Drug Conjugates Market
o Nigeria Antibody Drug Conjugates Market
o South Africa Antibody Drug Conjugates Market
o Rest of MEA Antibody Drug Conjugates Market
Antibody Drug Conjugates Market, By Key Players
· Novartis AG
· Pfizer, Inc
· Genentech Inc
· Immunomedics, Inc
· Bayer Healthcare Pharmaceuticals
· F. Hoffman-La Roche Ltd
· Takeda Pharmaceutical Company Limited
· Seattle Genetics Inc
· Immunogen Inc
· Progenics Pharmaceuticals Inc
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Antibody Drug Conjugates Market, By Drugs
5.1. Introduction
5.2. Global Antibody Drug Conjugates Revenue and Market Share by Drugs (2017-2027)
5.2.1. Global Antibody Drug Conjugates Revenue and Revenue Share by Drugs (2017-2027)
5.3. Kadcyla
5.3.1. Global Kadcyla Revenue and Growth Rate (2017-2027)
5.4. Adcetris
5.4.1. Global Adcetris Revenue and Growth Rate (2017-2027)
6. Antibody Drug Conjugates Market, By Mechanism Of Action
6.1. Introduction
6.2. Global Antibody Drug Conjugates Revenue and Market Share by Mechanism Of Action (2017-2027)
6.2.1. Global Antibody Drug Conjugates Revenue and Revenue Share by Mechanism Of Action (2017-2027)
6.3. HER2 Antibodies
6.3.1. Global HER2 Antibodies Revenue and Growth Rate (2017-2027)
6.4. CD30 Antibodies
6.4.1. Global CD30 Antibodies Revenue and Growth Rate (2017-2027)
7. Antibody Drug Conjugates Market, By Application
7.1. Introduction
7.2. Global Antibody Drug Conjugates Revenue and Market Share by Application (2017-2027)
7.2.1. Global Antibody Drug Conjugates Revenue and Revenue Share by Application (2017-2027)
7.3. Lymphoma
7.3.1. Global Lymphoma Revenue and Growth Rate (2017-2027)
7.4. Breast Cancer
7.4.1. Global Breast Cancer Revenue and Growth Rate (2017-2027)
8. Antibody Drug Conjugates Market, By Region
8.1. Introduction
8.2. Global Antibody Drug Conjugates Revenue and Market Share by Regions
8.2.1. Global Antibody Drug Conjugates Revenue by Regions (2017-2027)
8.3. North America Antibody Drug Conjugates by Countries
8.3.1. North America Antibody Drug Conjugates Revenue and Growth Rate (2017-2027)
8.3.2. North America Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Antibody Drug Conjugates by Countries
8.4.1. Europe Antibody Drug Conjugates Revenue and Growth Rate (2017-2027)
8.4.2. Europe Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Antibody Drug Conjugates by Countries
8.5.1. Asia-Pacific Antibody Drug Conjugates Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Antibody Drug Conjugates by Countries
8.6.1. South America Antibody Drug Conjugates Revenue and Growth Rate (2017-2027)
8.6.2. South America Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Antibody Drug Conjugates by Countries
8.7.1. Middle East and Africa Antibody Drug Conjugates Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Novartis AG
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Financial Overview
9.2. Pfizer, Inc
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Financial Overview
9.3. Genentech Inc
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Financial Overview
9.4. Immunomedics, Inc
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Financial Overview
9.5. Bayer Healthcare Pharmaceuticals
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Financial Overview
9.6. Takeda Pharmaceutical Company Limited
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Financial Overview
9.7. Seattle Genetics Inc
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Financial Overview
9.8. Immunogen Inc
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Financial Overview
9.9. Progenics Pharmaceuticals Inc
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Financial Overview
10. Global Antibody Drug Conjugates Market Competition, by Manufacturer
10.1. Global Antibody Drug Conjugates Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Antibody Drug Conjugates Price By Region (2017-2017)
10.3. Top 5 Antibody Drug Conjugates Manufacturer Market Share
10.4. Market Competition Trend
11. Antibody Drug Conjugates Market Forecast (2017-2027)
11.1. Global Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Antibody Drug Conjugates Market Forecast by Regions (2017-2027)
11.2.1. North America Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.1.1. United States Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.1.2. Canada Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.1.3. Mexico Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.2. Europe Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.2.1. Germany Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.2.2. France Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.2.3. UK Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.2.4. Russia Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.2.5. Italy Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.3. Asia-Pacific Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.3.1. China Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.3.2. Japan Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.3.3. Korea Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.3.4. India Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.4. South America Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.4.1. Brazil Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.4.2. Argentina Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.4.3. Columbia Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.4.4. Rest of South America Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5. Middle East and Africa Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5.3. Egypt Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5.4. Nigeria Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5.5. South Africa Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5.6. Turkey Antibody Drug Conjugates Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Antibody Drug Conjugates Market Forecast (2017-2027)
11.3. Antibody Drug Conjugates Market Forecast by Drugs (2017-2027)
11.3.1. Antibody Drug Conjugates Forecast by Drugs (2017-2027)
11.3.2. Antibody Drug Conjugates Market Share Forecast by Drugs (2017-2027)
11.4. Antibody Drug Conjugates Market Forecast by Mechanism Of Action (2017-2027)
11.4.1. Antibody Drug Conjugates Forecast by Mechanism Of Action (2017-2027)
11.4.2. Antibody Drug Conjugates Market Share Forecast by Mechanism Of Action (2017-2027)
11.5. Antibody Drug Conjugates Market Forecast by Application (2017-2027)
11.5.1. Antibody Drug Conjugates Forecast by Application (2017-2027)
11.5.2. Antibody Drug Conjugates Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Antibody Drug Conjugates Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Antibody Drug Conjugates Revenue and Revenue Share by Drugs (2017-2018)
Figure Global Kadcyla Revenue and Growth Rate (2017-2018)
Figure Global Adcetris Revenue and Growth Rate (2017-2018)
Table Global Antibody Drug Conjugates Revenue and Revenue Share by Mechanism Of Action (2017-2018)
Figure Global HER2 Antibodies Revenue and Growth Rate (2017-2018)
Figure Global CD30 Antibodies Revenue and Growth Rate (2017-2018)
Table Global Antibody Drug Conjugates Revenue and Revenue Share by Application (2017-2018)
Figure Global Lymphoma Revenue and Growth Rate (2017-2018)
Figure Global Breast Cancer Revenue and Growth Rate (2017-2018)
Table Global Antibody Drug Conjugates Revenue by Regions (2017-2018)
Figure North America Antibody Drug Conjugates Growth Rate (2017-2018)
Figure North America Antibody Drug Conjugates Revenue and Growth Rate (2017-2018)
Figure North America Antibody Drug Conjugates by Countries (2017-2018)
Figure North America Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2018)
Figure United States Antibody Drug Conjugates Growth Rate (2017-2018)
Figure United States Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Canada Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Mexico Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Europe Antibody Drug Conjugates Revenue and Growth Rate (2017-2018)
Figure Europe Antibody Drug Conjugates by Countries (2017-2018)
Figure Europe Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2018)
Figure Germany Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Germany Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Antibody Drug Conjugates Growth Rate (2017-2018)
Figure France Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Antibody Drug Conjugates Growth Rate (2017-2018)
Figure UK Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Russia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Italy Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Rest of Europe Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Asia-Pacific Antibody Drug Conjugates Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Antibody Drug Conjugates by Countries (2017-2018)
Figure Asia-Pacific Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2018)
Figure China Antibody Drug Conjugates Growth Rate (2017-2018)
Figure China Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Japan Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Korea Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Antibody Drug Conjugates Growth Rate (2017-2018)
Figure India Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Southeast Asia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Antibody Drug Conjugates Growth Rate (2017-2018)
Figure South America Antibody Drug Conjugates Revenue and Growth Rate (2017-2018)
Figure South America Antibody Drug Conjugates by Countries (2017-2018)
Figure South America Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Brazil Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Argentina Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Columbia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Rest of South America Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Middle East and Africa Antibody Drug Conjugates Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Antibody Drug Conjugates by Countries (2017-2018)
Figure Middle East and Africa Antibody Drug Conjugates Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Saudi Arabia Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Antibody Drug Conjugates Growth Rate (2017-2018)
Figure United Arab Emirates Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Egypt Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Nigeria Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Antibody Drug Conjugates Growth Rate (2017-2018)
Figure South Africa Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Turkey Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Antibody Drug Conjugates Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2017-2018)
Table Novartis AG Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer, Inc Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Genentech Inc Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Immunomedics, Inc Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bayer Healthcare Pharmaceuticals Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Takeda Pharmaceutical Company Limited Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Seattle Genetics Inc Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Immunogen Inc Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Progenics Pharmaceuticals Inc Antibody Drug Conjugates Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Antibody Drug Conjugates Market Share by Manufacturer
Figure Global Antibody Drug Conjugates Revenue and Market Share by Manufacturer
Table Global Antibody Drug Conjugates Price by Region (2017-2017)
Figure Top 5 Antibody Drug Conjugates Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Antibody Drug Conjugates Revenue (Millions USD) and Growth Rate (2018-2025)
Table Antibody Drug Conjugates Market Forecast by Regions (2018-2025)
Figure North America Antibody Drug Conjugates Market Forecast (2018-2025)
Figure United States Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Canada Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Mexico Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Europe Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Germany Antibody Drug Conjugates Market Forecast (2018-2025)
Figure France Antibody Drug Conjugates Market Forecast (2018-2025)
Figure UK Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Russia Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Italy Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Rest of Europe Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Asia-Pacific Antibody Drug Conjugates Market Forecast (2018-2025)
Figure China Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Japan Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Korea Antibody Drug Conjugates Market Forecast (2018-2025)
Figure India Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Southeast Asia Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Antibody Drug Conjugates Market Forecast (2018-2025)
Figure South America Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Brazil Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Argentina Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Columbia Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Rest of South America Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Middle East and Africa Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Saudi Arabia Antibody Drug Conjugates Market Forecast (2018-2025)
Figure United Arab Emirates Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Egypt Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Nigeria Antibody Drug Conjugates Market Forecast (2018-2025)
Figure South Africa Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Turkey Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Antibody Drug Conjugates Market Forecast (2018-2025)
Figure Global Antibody Drug Conjugates Forecast by Drugs (2018-2025)
Figure Global Antibody Drug Conjugates Market Share Forecast by Drugs (2018-2025)
Figure Global Antibody Drug Conjugates Forecast by Drugs (2018-2025)
Figure Global Antibody Drug Conjugates Forecast by Mechanism Of Action (2018-2025)
Figure Global Antibody Drug Conjugates Market Share Forecast by Mechanism Of Action (2018-2025)
Figure Global Antibody Drug Conjugates Forecast by Mechanism Of Action (2018-2025)
Figure Global Antibody Drug Conjugates Forecast by Application (2018-2025)
Figure Global Antibody Drug Conjugates Market Share Forecast by Application (2018-2025)
Figure Global Antibody Drug Conjugates Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|